Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHANECCO '17 Barcelona
Year: 2017
Authors:

Ledder O.*1, de Meij T.2, Martín de Carpi J.3, Richmond L.4, Cohen S.5, Bronsky J.6, Shaoul R.7, Levine A.8, Escher J.9, deRidder L.9, Assa A.10, Ruemmele F.11, Shah N.12, Wolters V.13, Rodrigues A.14, Uhlig H.14, Urlep D.15, Posovsky C.16, Kolho K.17, Turner D.1

1Shaare Zedek Medical Center, Pediatric Gastroenterology, Jerusalem, Israel 2VU Medical Centre, Amsterdam, Netherlands 3Hospital Sant Joan de Deu, Barcelona, Spain 4Royal Hospital for Sick Children, Glasgow, United Kingdom 5Dana Medical Center, Tel Aviv, Israel 6University Hospital Motol, Prague, Czech Republic 7Rambam Medical Center, Haifa, Israel 8Wolfson Medical Center, Holon, Israel 9Erasmus Medical Center, Rotterdam, Netherlands 10Schneider Medical Center, Petach Tikva, Israel 11Hopital Necker Enfants Malades, Paris, France 12Great Ormond Street Hospital, London, United Kingdom 13University Medical Center Utrecht, Utrecht, Netherlands 14Oxford University Hospital, Oxford, United Kingdom 15Ljubljana University Medical Center, Ljubljana, Slovenia 16University Medical Center, Ulm, Germany 17Helsinki University Central Hospital, Helsinki, Finland

P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011ECCO '17 Barcelona
Year: 2017
Authors:

Narula N.*1, Borges L.2, Steinhart A.H.3, Colombel J.-F.4

1McMaster University, Gastroenterology, Hamilton, Canada 2Brigham and Women's Hospital, Boston, United States 3Mount Sinai Hospital, Toronto, Canada 4Mount Sinai Hospital, Gastroenterology, New York, United States

P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experienceECCO '17 Barcelona
Year: 2017
Authors:

Plevris N., Manship T.A., Deekae A., Jones G.R., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexateECCO '17 Barcelona
Year: 2017
Authors:

Peixoto A., Silva M., Morais R., Liberal R., Gonçalves R., Lopes S., Macedo G.

Centro Hospitalar São João, Gastroenterology, Porto, Portugal

P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trialECCO '17 Barcelona
Year: 2017
Authors:

Lekkerkerker A., Harder B., Kulkarni P., Zhao R., Choi M., Noyes A., Polihrom A., Fillos D., Rae J., Danilenko D., Stefanich E., Herman A., Lu T.

Genentech, Research and Early Development, South San Francisco, United States

P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Yoshihara T., Shinzaki S., Kawai S., Iwatani S., Yamaguchi T., Araki M., Hiyama S., Inoue T., Hayashi Y., Watabe K., Iijima H., Takehara T.

Osaka university, Gastroenterology and Hepatology, Suita, Osaka, Japan

P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrenceECCO '17 Barcelona
Year: 2017
Authors:

Auzolle C.*1, Houze P.2, Tran-Minh M.-L.1, Nancey S.3, Buisson A.4, Fumery M.5, Pariente B.6, Djenidi F.1, Marteau P.7, Bouhnik Y.8, Seksik P.7, Allez M.7

1Saint-Louis Hospital, Department of Gastroenterology, Paris, France 2Saint-Louis Hospital, Department of Biochemistry, Paris, France 3Lyon-Sud Hospital, Hospices Civils de Lyon, Department of Gastroenterology, Pierre-Benite, France 4CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 5CHU Amiens, Department of Gastroenterology, Amiens, France 6Claude Huriez Hospital, Department of Gastroenterology, Lille, France 7Saint-Antoine Hospital, Department of Gastroenterology, Paris, France 8Beaujon Hospital, Department of Gastroenterology, Clichy, France

P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece 2Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece 3University of Oxford, Harris Manchester College, Oxford, United Kingdom

P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assayECCO '17 Barcelona
Year: 2017
Authors:

Roseth A.*1, Lindsjô I.2, Malmstrøm G.-H.3

1Lovisenberg Hospital, Medicine, Oslo, Norway 2Lovisenberg Diakonale Hospital, Deparment Of Gastroenterology, Oslo, Norway 3UngerVetlesen Institute, Oslo, Norway

P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trialECCO '17 Barcelona
Year: 2017
Authors:

Casellas F.*1, Barreiro-de Acosta M.2, Esteve M.3, Castro-Laria L.4, Vicente R.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Boudet J.M.5, Rodríguez-San Pedro L.13, Díaz G.13, Casado R.13, Marín I.14

1Hospital Universitari Vall Hebron, Barcelona, Spain, Barcelona, Spain 2Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain 3Hospital Universitari Mutua Terrassa, Barcelona, Spain 4Hospitales Universitarios Virgen Macarena-Rocío, Sevilla, Spain 5Hospital Universitario Miguel Servet, Zaragoza, Spain 6Dr. Negrin University Hospital, Las Palmas, Spain 7Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain 8Hospital Universitario la Paz, Madrid, Spain 9Hospital Universitari Dr. Josep Trueta, Girona, Spain 10Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 11Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain 12Hospital General Universitario de Valencia, Valencia, Spain 13Abbvie, Madrid, Spain 14Hospital Universitario Gregorio Marañόn, Madrid, Spain

P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapyECCO '17 Barcelona
Year: 2017
Authors:

Parra R.S., Feitosa M.R., Féres O., Rocha J.J.R.d.

University of São Paulo, Department of Surgery and Anatomy, Ribeirão Preto, Brazil

P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Kaniewska M.*1, Moniuszko A.1, Maciejewska K.1, Rydzewska G.1,2

1Central Clinical Hospital of Ministry of Internal Affairs and Administration, Warsaw, Poland, Gastroenterology, Warsaw, Poland 2Faculty of Medicine and Health Science, UJK, Kielce, Poland, Kielce, Poland

P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patientsECCO '17 Barcelona
Year: 2017
Authors:

Greener T.*1, Kabakchiev B.2, Silverberg M.3

1Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada 2Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex Zane Cohen Centre for, Toronto, Canada 3University of Toronto, Gastroenterology Division, Toronto, Canada

P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximabECCO '17 Barcelona
Year: 2017
Authors:

Nishida Y.*1, Hosomi S.1, Watanabe K.2, Yukawa T.1, Otani K.1, Nagami Y.1, Tanaka F.1, Taira K.1, Kamata N.1, Shiba M.1, Yamagami H.1, Tanigawa T.1, Watanabe T.1, Tominaga K.1, Fujiwara Y.1

1Osaka City University, Gastroenterology, Osaka, Japan 2Osaka General Hospital, Osaka, Japan

P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian populationECCO '17 Barcelona
Year: 2017
Authors:

Mao R.1, Guo J.1, Ben Horin S.1,2, Chen M.*3

1The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China 2Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel 3The first affiliated hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P429: Mucosal healing after 3 months of conventional IBD treatment: real life dataECCO '17 Barcelona
Year: 2017
Authors:

Carlsen A.*1, Tvedt-Gundersen E.1, Isaksen K.1, Leitao K.Ø.1, Karlsen L.N.1, Omdal R.1,2, Aabakken L.3, Grimstad T.1

1Stavanger University Hospital, Department of Internal Medicine, Stavanger, Norway 2University of Bergen, Department of Clinical Science, Bergen, Norway 3Oslo University Hospital, Deaprtment of Gastroenterology, Oslo, Norway

P430: EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experienceECCO '17 Barcelona
Year: 2017
Authors:

Nugent S.*1, Nugent M.2, Mullane D.1, Kelly C.1

1Whitfield Clinic, Gastroenterology, Waterford, Ireland 2Trinity College Dublin, Medical School, Dublin, Ireland

P431: Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab doseECCO '17 Barcelona
Year: 2017
Authors:

Fuh F., Tew W., Keir M., Looney C., Maciuca R., McBride J., Ramirez-Montagut T.

Genentech, South San Francisco, United States

P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Sebastian S.*1,2, Tzivinikos C.3, Drskova T.4, Hradsky O.4, Nair M.V.1,5, Sahnan K.6, Muhammed R.7, Devadason D.8, Parmar R.S.3, Crook K.6, Akbar A.6, Thomson M.5, Hart A.L.6

1Hull & East Yorkshire NHS Trust, Hull, United Kingdom 2Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom 3Alder Hey Children's Hospital, Liverpool, United Kingdom 4Motol University Hospital, Prague, Czech Republic 5Sheffied Children's Hospitals NHS Foundation Trust, Sheffiled, United Kingdom 6St Marks Hospital, London, United Kingdom 7Birmingham Children's Hospital, Birmingham, United Kingdom 8Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII groupECCO '17 Barcelona
Year: 2017
Authors:

García Albert A.M.1, García-Paredes R.*2, Torrella Cortés E.3, Martinez-Jimenez T.4, Angel Rey J.M.4, García-Tercero I.2, Castillo Espinosa J.M.5, Torregrosa Lloret M.3, Chacόn Martínez S.3, Andreu Plaza J.6, Rodríguez Lozano A.2

1Reina Sofía-Murcia Hospital, Gastroenterology, Murcia, Spain 2Santa Lucía Hospital, Gastroenterology, Cartagena, Spain 3Morales Meseguer Hospital, Gastroenterology, Murcia, Spain 4Rafael Mendez Hospital, Gastroenterology, Lorca, Spain 5Los Arcos Hospital, Digestive Disease, Cartagena, Spain 6Virgen del Castillo Hospital, Gastroenterology, Yecla, Spain